Huge Becomes an Associated Partner of the Flemingsberg Science Foundation

Flemingsberg, June 19, 2024

The Flemingsberg Science Foundation announces today that the property company Huge is becoming an associated partner of the foundation. Through this partnership, Huge aligns with the foundation’s purposes and goals.

“It is extremely gratifying that Huge is now joining as an associated partner to the foundation. Huge, with both residential, student housing, and commercial premises in Flemingsberg, plays a very important role in an attractive Flemingsberg both today and in the future. Knowing that we can bring together Huge, Hemsö, and Fabege along with Botkyrka and Huddinge municipalities this autumn to accelerate the establishment work makes me both proud and grateful,” says Johnny Högberg, CEO of the Flemingsberg Science Foundation.

In the foundation’s strategic plan for the period 2022-2025, the importance of attracting new partners and stakeholders who share our vision and see the value in investing in both the foundation’s operations and Flemingsberg’s site development is emphasized. Partnerships like these are thus crucial for Flemingsberg’s progress and the pace of its continued development.

“Huge Bostäder owns a large property portfolio in Flemingsberg, which we are reinvesting heavily in over a ten-year period. Additionally, we are now building Studenten 1, comprising 210 rental apartments, five retail spaces, and a large preschool. For Huge, it is important to be a long-term partner in the development of Flemingsberg; we want to be involved and make a difference.” – Karin Strömberg Ekström, CEO of Huge Bostäder.

The main focus of the partnership will be in line with the foundation’s goal of making Flemingsberg the first choice for establishments in southern Stockholm. Through this partnership, we open up new opportunities to drive projects and initiatives in areas such as site development, packaging, and marketing of Flemingsberg. Additionally, the inclusion of associate partners means an increase in diversity and expertise within the foundation. We continue to actively work to strengthen our partnership with more actors who share our vision of investing in both Flemingsberg’s operations and its future development.

Johnny Högberg
CEO Flemingsberg Science Foundation
070 550 12 73

OptiCell Solutions – A Key Player in Cell and Gene Therapy Establishes in Flemingsberg

Flemingsberg continues to be a natural choice for knowledge-intensive and innovative businesses. OptiCell Solutions is a company that recently launched its operations at Novum Labs on the Flemingsberg Campus. Founded in 2024 by specialists from Karolinska University Hospital and entrepreneurs from the Life Science industry, the company specializes in improving the availability of high-quality target cells for cell and gene therapies, a critical component of the growing ATMP (Advanced Therapy Medicinal Products) sector.

Drivhuset Stockholm – Where Future Entrepreneurs Take Their First Steps

Imagine a place where young ideas are free to grow, where passion meets ambition, and where the entrepreneurs of tomorrow take their first steps toward greatness. That’s exactly what Drivhuset Stockholm offers – a springboard for the next generation of entrepreneurs. Located on Campus Flemingsberg, we support students every day as they bring their ideas to life and build the skills needed to create real change. Our mission? To provide them with a safe, inspiring environment where they can test and develop their business ideas for real.

Hitchhiker’s Guide to Startup Success: Mastering the Art of the Perfect Pitch

Earlier this fall, we launched the first event in our seminar series, Hitchhiker’s Guide to Startup Success, which we are organizing together with Miltenyi Biotec. The inaugural session featured an inspiring workshop led by pitch expert and coach Malcolm Larri. The event gathered innovators and entrepreneurs in the Life Sciences sector, with a particular focus on Advanced Therapy Medicinal Products (ATMP)—a rapidly growing field with tremendous potential to revolutionize healthcare.

12 Next